Novel Rx
6 months 2 weeks ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024
6 months 2 weeks ago
IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1
Is it safe? looks it, no serious AES, 6mo follow up
Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab
Does it work? will have to wait for Phase 2
Somehow bold knowing TCZ did not work in hand OA
AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM
6 months 2 weeks ago
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s.
This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too
ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr
6 months 2 weeks ago
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
6 months 2 weeks ago
Points to consider in pregnancy in
#rheumatic diseases
3 points
✅TNFi all OK 👍
? Only if you can’t control disease use other #bDMARDs
Baby #vaccinations if exposed to #biologics while present
#rotovirus ok
other live vaccines >6 mos
#EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
6 months 2 weeks ago
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
6 months 2 weeks ago
EULAR guidelines for screening for TB in rheumatic disease patients
#EULAR2024 https://t.co/jaixl8lGkY
6 months 2 weeks ago
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
6 months 2 weeks ago
Maintenance of remission in GPA/MPA.
RTX for 48 months sounds good to me.
#EULAR2024 https://t.co/5YGwOHhCuX